KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) EBIT Margin (2016 - 2025)

Regeneron Pharmaceuticals has reported EBIT Margin over the past 17 years, most recently at 22.65% for Q4 2025.

  • Quarterly results put EBIT Margin at 22.65% for Q4 2025, down 348.0% from a year ago — trailing twelve months through Dec 2025 was 24.95% (down 315.0% YoY), and the annual figure for FY2025 was 24.95%, down 315.0%.
  • EBIT Margin for Q4 2025 was 22.65% at Regeneron Pharmaceuticals, down from 27.35% in the prior quarter.
  • Over the last five years, EBIT Margin for REGN hit a ceiling of 2517.0% in Q1 2022 and a floor of 19.54% in Q1 2025.
  • Median EBIT Margin over the past 5 years was 31.94% (2023), compared with a mean of 352.93%.
  • Biggest five-year swings in EBIT Margin: soared 247300bps in 2022 and later crashed -248706bps in 2023.
  • Regeneron Pharmaceuticals' EBIT Margin stood at 2199.75% in 2021, then dropped by -20bps to 1764.31% in 2022, then crashed by -98bps to 28.33% in 2023, then dropped by -8bps to 26.13% in 2024, then fell by -13bps to 22.65% in 2025.
  • The last three reported values for EBIT Margin were 22.65% (Q4 2025), 27.35% (Q3 2025), and 29.37% (Q2 2025) per Business Quant data.